Pierre Fabre Medicament — CureCurrent

Published trials26

Recruiting shown6

Roles2

SourceClinicalTrials.gov

Clinical trials

26 shown

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET AlterationsNCT06669117 · lead sponsor · 2024-10-22

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIsNCT06567015 · lead sponsor · 2024-09-17

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion MutationsNCT06043817 · lead sponsor · 2023-09-26

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsNCT04913285 · lead sponsor · 2021-08-04

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyNCT03394365 · lead sponsor · 2017-12-29

An Observational Real-world Study to Evaluate the Impact of Dermatological Toxicities on the Quality of Life in Patients With Early Breast Cancer Treated With Adjuvant Endocrine Therapy - BCARE (Breast Cancer Adjuvant Real-world Evaluation of Dermatological Adverse Events)NCT06690489 · lead sponsor · 2024-11-22

To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of TreatmentNCT06500494 · lead sponsor · 2024-09-10

ACTIVE_NOT_RECRUITING

Treatment Patterns of Neratinib in HER2+ EBC in ChinaNCT05491057 · lead sponsor · 2022-09-30

A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With NeratinibNCT05599334 · lead sponsor · 2022-07-05

A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)NCT05546905 · lead sponsor · 2022-06-23

Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung CancerNCT05195632 · lead sponsor · 2022-06-02

ACTIVE_NOT_RECRUITING

F17464 in Acute Schizophrenia TrialNCT02151656 · lead sponsor · 2014-06-01

Efficacy and Safety of V0111 Cream on Open Cracked Heel in Diabetic Patients With Polyneuropathy.NCT02045199 · lead sponsor · 2014-02-01

Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerNCT01953003 · lead sponsor · 2013-09-01

Bronchodilator Properties and Safety in AsthmaNCT01951222 · lead sponsor · 2013-09-01

Efficacy and Safety Study of F373280NCT01831856 · lead sponsor · 2013-04-01

Safety, Preliminary Pharmacokinetics and Bronchodilator Properties of V0162NCT01348555 · lead sponsor · 2011-04-01

Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast CancerNCT01091168 · lead sponsor · 2009-07-01

Trial of Vinflunine Plus Capecitabine in Advanced Breast CancerNCT01095003 · lead sponsor · 2009-05-01

Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast CancerNCT03887130 · lead sponsor · 2007-03-27

A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast CancerNCT02054338 · lead sponsor · 2006-06-01

Oral Vinorelbine as Induction Chemotherapy Followed Concomitant ChemoradiotherapyNCT01839032 · lead sponsor · 2005-05-01

Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung CancerNCT00683514 · lead sponsor · 2005-04-01

Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)NCT03848052 · collaborator · 2017-10-02

Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung CancerNCT03801304 · collaborator · 2019-01-24

A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced DiseaseNCT02730091 · collaborator · 2016-02-24

Sponsor roles

lead sponsor23

collaborator3

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.